A real-world study presented at a recent conference evaluated the effectiveness and safety of switching to a single-tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in adults with HIV who had detectable viremia. The findings support the use of this switch strategy in clinical practice.
The study, which analyzed data from a cohort of patients with HIV, showed that most individuals who switched to BIC/FTC/TAF achieved viral suppression. The results indicate that the regimen is a viable option for patients who need to change therapy due to virologic failure or other reasons.
Researchers noted that the switch was generally well-tolerated, with no new safety concerns identified. The data add to the growing body of evidence supporting the use of BIC/FTC/TAF in diverse patient populations, including those with prior viremia.
Experts emphasize that individualized treatment decisions remain crucial, and the findings should be considered alongside other clinical factors. Further research is ongoing to confirm these results in larger, more diverse cohorts.
